Rat As a Predictive Model for Human Clearance and Bioavailability of Monoclonal Antibodies

Overview

Journal Antibodies (Basel)

Date 2025 Jan 23

PMID 39846610

Authors

Jason D Robarge

Kevin M Budge

Lucy Her

Andrea M Patterson

Patricia Brown-Augsburger

Affiliations

Soon will be listed here.

Abstract

Background: The prediction of human clearance (CL) and subcutaneous (SC) bioavailability is a critical aspect of monoclonal antibody (mAb) selection for clinical development. While monkeys are a well-accepted model for predicting human CL, other preclinical species have been less-thoroughly explored. Unlike CL, predicting the bioavailability of SC administered mAbs in humans remains challenging as contributing factors are not well understood, and preclinical models have not been systematically evaluated.

Methods: Non-clinical and clinical pharmacokinetic (PK) parameters were mined from public and internal sources for rats, cynomolgus monkeys, and humans. Intravenous (IV) and SC PK was determined in Sprague Dawley rats for fourteen mAbs without existing PK data. Together, we obtained cross-species data for 25 mAbs to evaluate CL and SC bioavailability relationships among rats, monkeys, and humans.

Results: Rat and monkey CL significantly correlated with human CL and supported the use of species-specific exponents for body-weight-based allometric scaling. Notably, rat SC bioavailability significantly correlated with human SC bioavailability, while monkey SC bioavailability did not. Bioavailability also correlated with clearance.

Conclusions: The rat model enables an early assessment of mAb PK properties, allowing discrimination among molecules in the discovery pipeline and prediction of human PK. Importantly, rat SC bioavailability significantly correlated with human SC bioavailability, which has not been observed with other species. Rats are cost-effective and efficient relative to monkeys and provide a valuable tool for pharmacokinetic predictions in therapeutic antibody discovery.

References

Kraft T, Richter W, Emrich T, Knaupp A, Schuster M, Wolfert A . Heparin chromatography as an predictor for antibody clearance rate through pinocytosis. MAbs. 2019; 12(1):1683432. PMC: 6927760. DOI: 10.1080/19420862.2019.1683432. View

Tang Y, Li X, Cao Y . Which factors matter the most? Revisiting and dissecting antibody therapeutic doses. Drug Discov Today. 2021; 26(8):1980-1990. PMC: 8410626. DOI: 10.1016/j.drudis.2021.04.022. View

Collins D, Sanchez-Felix M, Badkar A, Mrsny R . Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics. J Control Release. 2020; 321:475-482. DOI: 10.1016/j.jconrel.2020.02.036. View

Bender C, Eichling S, Franzen L, Herzog V, Ickenstein L, Jere D . Evaluation of In Vitro Tools to Predict the In Vivo Absorption of Biopharmaceuticals Following Subcutaneous Administration. J Pharm Sci. 2022; 111(9):2514-2524. DOI: 10.1016/j.xphs.2022.04.005. View

Betts A, Keunecke A, van Steeg T, van der Graaf P, Avery L, Jones H . Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. MAbs. 2018; 10(5):751-764. PMC: 6150614. DOI: 10.1080/19420862.2018.1462429. View

OBrien K, Bhatia A, Tsen F, Chen M, Wong A, Woodley D . Identification of the critical therapeutic entity in secreted Hsp90α that promotes wound healing in newly re-standardized healthy and diabetic pig models. PLoS One. 2014; 9(12):e113956. PMC: 4252061. DOI: 10.1371/journal.pone.0113956. View

Liu L . Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2017; 9(1):15-32. PMC: 5777971. DOI: 10.1007/s13238-017-0408-4. View

Sharma R, Wang W, Rasmussen J, Joshi A, Houston J, Adams K . Quantitative imaging of lymph function. Am J Physiol Heart Circ Physiol. 2007; 292(6):H3109-18. DOI: 10.1152/ajpheart.01223.2006. View

Dahlberg A, Kaminskas L, Smith A, Nicolazzo J, Porter C, Bulitta J . The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats. Mol Pharm. 2013; 11(2):496-504. DOI: 10.1021/mp400464s. View

10.

Zheng Y, Tesar D, Benincosa L, Birnbock H, Boswell C, Bumbaca D . Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. MAbs. 2012; 4(2):243-55. PMC: 3361660. DOI: 10.4161/mabs.4.2.19387. View

11.

Richter W, Bhansali S, Morris M . Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012; 14(3):559-70. PMC: 3385825. DOI: 10.1208/s12248-012-9367-0. View

12.

Mahmood I . A Single Animal Species-Based Prediction of Human Clearance and First-in-Human Dose of Monoclonal Antibodies: Beyond Monkey. Antibodies (Basel). 2021; 10(3). PMC: 8477747. DOI: 10.3390/antib10030035. View

13.

Haraya K, Tachibana T . Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations. BioDrugs. 2022; 37(1):99-108. PMC: 9709760. DOI: 10.1007/s40259-022-00566-2. View

14.

Avery L, Wang M, Kavosi M, Joyce A, Kurz J, Fan Y . Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs. 2016; 8(6):1064-78. PMC: 4968115. DOI: 10.1080/19420862.2016.1193660. View

15.

Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J . Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol. 2009; 54(2):164-82. DOI: 10.1016/j.yrtph.2009.03.012. View

16.

Haraya K, Tachibana T, Nezu J . Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human. Drug Metab Pharmacokinet. 2017; 32(4):208-217. DOI: 10.1016/j.dmpk.2017.05.002. View

17.

Richter W, Jacobsen B . Subcutaneous absorption of biotherapeutics: knowns and unknowns. Drug Metab Dispos. 2014; 42(11):1881-9. DOI: 10.1124/dmd.114.059238. View

18.

Kagan L, Zhao J, Mager D . Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. Pharm Res. 2014; 31(12):3265-73. PMC: 4469501. DOI: 10.1007/s11095-014-1416-1. View

19.

Lu R, Hwang Y, Liu I, Lee C, Tsai H, Li H . Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020; 27(1):1. PMC: 6939334. DOI: 10.1186/s12929-019-0592-z. View

20.

Datta-Mannan A, Witcher D, Lu J, Wroblewski V . Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys. MAbs. 2012; 4(2):267-73. PMC: 3361662. DOI: 10.4161/mabs.4.2.19364. View